7-Hydroxyquinolinone COA and Purity Specifications for Pharmaceutical Intermediates
- Critical Quality Assurance: Comprehensive COA validation ensures CAS 70500-72-0 meets strict pharmaceutical intermediate standards.
- Advanced Analytics: Utilization of HPLC, NMR, and Mass Spectrometry guarantees accurate impurity profiling and structural confirmation.
- Bulk Supply Reliability: Secure consistent industrial purity and competitive bulk pricing for large-scale production runs.
In the complex landscape of pharmaceutical intermediate synthesis, the reliability of raw materials dictates the success of the final active pharmaceutical ingredient (API). 7-Hydroxy-1H-quinolin-2-one (CAS: 70500-72-0) serves as a critical building block, particularly in the production of antipsychotic medications such as Brexpiprazole. For process chemists and procurement managers, understanding the nuances of the Certificate of Analysis (COA) and purity specifications is paramount. This document details the technical requirements for validating this compound, ensuring that every batch meets the rigorous demands of modern drug manufacturing.
At NINGBO INNO PHARMCHEM CO.,LTD., we recognize that variability in intermediate quality can lead to significant downstream processing issues. Therefore, our quality control protocols focus on precise quantification of the main component and the identification of related substances. This article outlines the essential parameters found in a robust COA, the analytical methods used for validation, and the importance of maintaining high industrial purity throughout the supply chain.
Understanding Certificate of Analysis (COA) Parameters for CAS 70500-72-0
A comprehensive COA is more than a compliance document; it is a technical roadmap verifying the chemical identity and quality of the material. For 7-hydroxyquinolinone, the COA must explicitly detail the batch number, manufacturing date, and expiration date to ensure traceability. However, the core value lies in the quantitative data regarding purity and impurities.
Standard specifications typically require a minimum assay of 98.0% to 99.0% for pharmaceutical-grade intermediates. The COA should also list limits for critical impurities, such as residual solvents, heavy metals, and specific process-related byproducts. When evaluating a supplier, buyers must ensure that the testing methods referenced in the COA align with pharmacopeial standards or validated internal methods. Transparency in these parameters reduces the risk of batch rejection during API synthesis.
Key Specification Metrics
To maintain consistency in the synthesis route for downstream APIs, the following metrics are strictly monitored:
- Assay (Purity): Determined via HPLC, ensuring the main peak area corresponds to the required percentage.
- Related Substances: Identification of isomers or incomplete reaction products that could affect catalytic steps.
- Loss on Drying: Verification of moisture content to prevent hydrolysis during storage or reaction.
- Residual Solvents: Compliance with ICH Q3C guidelines for Class 1, 2, and 3 solvents.
Analytical Methods Used: HPLC, NMR, and MS Validation
Accurate characterization of 7-hydroxy-2-quinolone derivatives requires a multi-instrument approach. Relying on a single analytical technique can obscure structural nuances or impurity profiles. Our quality assurance laboratories employ a combination of chromatographic and spectroscopic methods to validate every batch.
High-Performance Liquid Chromatography (HPLC) is the primary method for determining purity. Using reverse-phase columns with UV detection, analysts can separate the target compound from closely related analogs. The method must be validated for specificity, linearity, accuracy, and precision. Additionally, 1H-NMR spectroscopy provides structural confirmation, ensuring that the chemical shifts correspond to the expected quinolinone scaffold rather than potential regioisomers like 7-Hydroxycarbostyril variants that may arise during cyclization.
Mass Spectrometry (MS) further corroborates the molecular weight, detecting any unexpected adducts or degradation products. For materials intended for sensitive biological assays or advanced material science applications, this level of characterization is non-negotiable. It ensures that the chemical behavior observed in the lab matches the theoretical properties of quinoline-2,7-diol structures.
Ensuring ≥98% Purity for Pharmaceutical Intermediate Use
The transition from laboratory scale to commercial production hinges on the consistency of industrial purity. Impurities in CAS 70500-72-0 can poison catalysts or lead to difficult-to-remove byproducts in the final API. Therefore, maintaining a purity profile of ≥98% is standard for high-quality intermediates.
Procurement teams must evaluate not just the initial purity but the stability of the compound under recommended storage conditions. Proper packaging and inert atmosphere storage are often required to prevent oxidation. When assessing the bulk price of materials, it is essential to factor in the cost of potential reprocessing if purity specifications are not met upon arrival. Sourcing from a reliable global manufacturer ensures that these quality standards are embedded in the manufacturing process rather than just tested at the end.
Typical Quality Control Table
| Test Item | Specification | Typical Result |
|---|---|---|
| Appearance | Off-white to Light Yellow Powder | Complies |
| Identification (IR/NMR) | Consistent with Reference Standard | Complies |
| Assay (HPLC) | ≥ 98.0% | 98.5% - 99.2% |
| Related Substances | ≤ 1.0% (Total) | 0.4% |
| Loss on Drying | ≤ 0.5% | 0.2% |
| Residual Solvents | Complies with ICH Q3C | Complies |
Strategic Procurement and Supply Chain Security
Securing a stable supply of 7-hydroxyquinolin-2-one requires a partnership with a manufacturer capable of scaling production without compromising quality. Fluctuations in raw material availability can disrupt API manufacturing schedules. Therefore, establishing a long-term contract with a verified supplier is crucial for risk mitigation.
Buyers should request full documentation packages, including Safety Data Sheets (SDS), Product Specifications (PS), and Certificates of Origin (COO). These documents facilitate customs clearance and regulatory compliance in various jurisdictions. NINGBO INNO PHARMCHEM CO.,LTD. specializes in providing these comprehensive documentation sets alongside technical support to ensure seamless integration into your production workflow.
In conclusion, the integrity of your pharmaceutical synthesis depends on the quality of your intermediates. By prioritizing detailed COA review, robust analytical validation, and secure supply chains, manufacturers can ensure the efficacy and safety of their final products. Focus on partners who demonstrate transparency in their manufacturing process and commitment to high-purity standards.